Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Chimeric Therapeutics (CHM) has manufactured its phase one plasmids for its clinical trial for the treatment of neuroendocrine and colorectal tumors
  • The completion enables the company to progress to research vector manufacturing plus advancement of technical operations in readiness for the CDH17 CAR T phase 1 clinical trial
  • The company says it’s pleased to achieve this key first step so rapidly after licensing
  • Meanwhile, Chimeric is also progressing its CLTX CAR T Phase 1 clinical trial in glioblastoma at The City of Hope Cancer Centre in California, where patients are now receiving second dose levels
  • Chimeric Therapeutics was up 0.81 per cent, trading at 31.3 cents at 2:03 pm AEDT.

Chimeric Therapeutics (CHM) has manufactured its phase one plasmids for its clinical trial.

CHM 2101 research grade plasmids have been manufactured, which the company said it considered a critical first step in the development of CDH17 CAR T.

CHM 2101 is a third generation CDH17 CAR T which is currently in preclinical development for treatment of neuroendocrine tumours, colorectal, pancreatic and gastric cancer.

Following a collaboration with the University of Pennsylvania, all research grade helper and transfer plasmids for the CDH17 CAR T have been completed and released.

“We are very pleased that we have been able to achieve this key first step so rapidly after licensing,” Chimeric’s CEO and Managing Director Jennifer Chow said.

“This accomplishment speaks to the commitment and drive that the Chimeric and University of Pennsylvania teams share to move this important CAR T forward to Phase 1 clinical trials.”

The completion enables the company to progress to research vector manufacturing, GMP plasmid and vector manufacturing, plus advancement of technical operations in readiness for the CDH17 CAR T phase 1 clinical trial.

Meanwhile, Chimeric is also progressing its CLTX CAR T Phase 1 clinical trial in glioblastoma (brain cancer) at The City of Hope Cancer Centre in California, where patients are now receiving second dose levels.

Chimeric Therapeutics was up 0.81 per cent, trading at 31.3 cents at 2:03 pm AEDT.

CHM by the numbers
More From The Market Herald
Rhythm Biosciences (ASX:RHY) - CEO, Glenn Gilbert

" Rhythm Biosciences (ASX:RHY) achieves CE Mark for ColoSTAT

Cancer diagnostic technology company Rhythm Biosciences (RHY) has achieved CE Mark certification for ColoSTAT.
EMVision Medical Devices (ASX:EMV) - CEO, Ron Weinberger

" EMVision Medical Devices (ASX:EMV) reports more strong results

Medical device maker EMVision (EMV) is spiking on the ASX today after releasing further results from a pilot clinical trial of its brain
ECS Botanics (ASX:ECS) - Managing Director and Founder, Alex Keach

" ECS Botanics’ (ASX:ECS) subsidiary buds $4.9m supply agreement

ECS Botanics’ (ECS) subsidiary has secured a $4.9 million agreement to supply resin to Australian cannabis company, Cannvalate.
Arovella Therapeutics (ASX:ALA) - CEO and Managing Director, Dr Michael Baker

" Arovella Therapeutics (ASX:ALA) receives $524,000 R&D tax refund

Arovella Therapeutics (ALA) has received a refund from the Australian Taxation Office (ATO) of just over $524,000 for the financial year.